Your browser doesn't support javascript.
loading
Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists.
Mohanty, Sambit K; Lobo, Anandi; Williamson, Sean R; Shah, Rajal B; Trpkov, Kiril; Varma, Murali; Sirohi, Deepika; Aron, Manju; Kandukari, Shivani R; Balzer, Bonnie L; Luthringer, Daniel L; Ro, Jae; Osunkoya, Adeboye O; Desai, Sangeeta; Menon, Santosh; Nigam, Lovelesh K; Sardana, Rohan; Roy, Paromita; Kaushal, Seema; Midha, Divya; Swain, Minakshi; Ambekar, Asawari; Mitra, Suvradeep; Rao, Vishal; Soni, Shailesh; Jain, Kavita; Diwaker, Preeti; Pattnaik, Niharika; Sharma, Shivani; Chakrabarti, Indranil; Sable, Mukund; Jain, Ekta; Jain, Deepika; Samra, Spinder; Vankalakunti, Mahesha; Mohanty, Subhashis; Parwani, Anil V; Sancheti, Sankalp; Kumari, Niraj; Jha, Shilpy; Dixit, Mallika; Malik, Vipra; Arora, Samriti; Munjal, Gauri; Gopalan, Anuradha; Magi-Galluzzi, Cristina; Dhillon, Jasreman.
Afiliación
  • Mohanty SK; Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, India.
  • Lobo A; Department of Pathology and Laboratory Medicine, Kapoor Urology Center and Pathology Laboratory, Raipur, India.
  • Williamson SR; Department of Pathology, Cleveland Clinic, Cleveland, OH, USA.
  • Shah RB; Department of Pathology, UT Southwestern University, Dallas, TX, USA.
  • Trpkov K; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.
  • Varma M; Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
  • Sirohi D; Department of Pathology, University of Utah, Salt Lake City, UT, USA.
  • Aron M; Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
  • Kandukari SR; Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
  • Balzer BL; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Luthringer DL; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Ro J; Department of Pathology and Genomic Medicine, Methodist Hospital, Houston, TX, USA.
  • Osunkoya AO; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
  • Desai S; Department of Pathology, Tata Memorial Hospital, Mumbai, India.
  • Menon S; Department of Pathology, Tata Memorial Hospital, Mumbai, India.
  • Nigam LK; Department of Pathology and Division of Renal and Urologic Pathology, Lal Pathology Laboratory, New Delhi, India.
  • Sardana R; Department of Pathology, Ampath Pathological Laboratory, Hyderabad, India.
  • Roy P; Department of Oncopathology, Tata Medical Center, Kolkata, India.
  • Kaushal S; Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Midha D; Department of Oncopathology, Tata Medical Center, Kolkata, India.
  • Swain M; Department of Pathology and Laboratory Medicine, Apollo Hospital, Hyderabad, India.
  • Ambekar A; Department of Pathology and Laboratory Medicine, Apollo Hospital, Mumbai, India.
  • Mitra S; Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bhubaneswar, India.
  • Rao V; Department of Pathology and Laboratory Medicine, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India.
  • Soni S; Department of Pathology and Laboratory Medicine, Muljibhai Patel Urological Hospital, Gujarat, India.
  • Jain K; Department of Pathology and Laboratory Medicine, Max Superspeciality Hospital, New Delhi, India.
  • Diwaker P; Department of Pathology, University College of Medical Sciences, New Delhi, India.
  • Pattnaik N; Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, India.
  • Sharma S; Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India.
  • Chakrabarti I; Department of Pathology, North Bengal Medical College, Siliguri, India.
  • Sable M; Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bhubaneswar, India.
  • Jain E; Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India.
  • Jain D; Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India.
  • Samra S; Department of Pathology, Dubbo Base Hospital, Dubbo, NSW, Australia.
  • Vankalakunti M; Department of Pathology and Laboratory Medicine, Manipal Hospital, Bangalore, India.
  • Mohanty S; Department of Histopathology, SUM Ultimate Medicare, Bhubaneswar, India.
  • Parwani AV; Department of Pathology, Wexner Medical Center, Ohio State University, Columbus, OH, USA.
  • Sancheti S; Department of Pathology and Laboratory Medicine, Homi Bhabha Cancer Hospital & Research Centre, Punjab (A Unit of Tata Memorial Centre, Mumbai), India.
  • Kumari N; Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Raebareli, India.
  • Jha S; Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, India.
  • Dixit M; Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India.
  • Malik V; Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India.
  • Arora S; Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India.
  • Munjal G; Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India.
  • Gopalan A; Department of Pathology, Memorial Sloan Kettering Cancer, New York, NY, USA.
  • Magi-Galluzzi C; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Dhillon J; Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.
Int J Surg Pathol ; 31(6): 993-1005, 2023 Sep.
Article en En | MEDLINE | ID: mdl-35946087
ABSTRACT
Background. Neuroendocrine differentiation in the prostate gland ranges from clinically insignificant neuroendocrine differentiation detected with markers in an otherwise conventional prostatic adenocarcinoma to a lethal high-grade small/large cell neuroendocrine carcinoma. The concept of neuroendocrine differentiation in prostatic adenocarcinoma has gained considerable importance due to its prognostic and therapeutic ramifications and pathologists play a pivotal role in its recognition. However, its awareness, reporting, and resource utilization practice patterns among pathologists are largely unknown. Methods. Representative examples of different spectrums of neuroendocrine differentiation along with a detailed questionnaire were shared among 39 urologic pathologists using the survey monkey software. Participants were specifically questioned about the use and awareness of the 2016 WHO classification of neuroendocrine tumors of the prostate, understanding of the clinical significance of each entity, and use of different immunohistochemical (IHC) markers. De-identified respondent data were analyzed. Results. A vast majority (90%) of the participants utilize IHC markers to confirm the diagnosis of small cell neuroendocrine carcinoma. A majority (87%) of the respondents were in agreement regarding the utilization of type of IHC markers for small cell neuroendocrine carcinoma for which 85% of the pathologists agreed that determination of the site of origin of a high-grade neuroendocrine carcinoma is not critical, as these are treated similarly. In the setting of mixed carcinomas, 62% of respondents indicated that they provide quantification and grading of the acinar component. There were varied responses regarding the prognostic implication of focal neuroendocrine cells in an otherwise conventional acinar adenocarcinoma and for Paneth cell-like differentiation. The classification of large cell neuroendocrine carcinoma was highly varied, with only 38% agreement in the illustrated case. Finally, despite the recommendation not to perform neuroendocrine markers in the absence of morphologic evidence of neuroendocrine differentiation, 62% would routinely utilize IHC in the work-up of a Gleason score 5 + 5 = 10 acinar adenocarcinoma and its differentiation from high-grade neuroendocrine carcinoma. Conclusion. There is a disparity in the practice utilization patterns among the urologic pathologists with regard to diagnosing high-grade neuroendocrine carcinoma and in understanding the clinical significance of focal neuroendocrine cells in an otherwise conventional acinar adenocarcinoma and Paneth cell-like neuroendocrine differentiation. There seems to have a trend towards overutilization of IHC to determine neuroendocrine differentiation in the absence of neuroendocrine features on morphology. The survey results suggest a need for further refinement and development of standardized guidelines for the classification and reporting of neuroendocrine differentiation in the prostate gland.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Tumores Neuroendocrinos / Carcinoma de Células Pequeñas / Carcinoma Neuroendocrino / Carcinoma de Células Grandes / Carcinoma de Células Acinares Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research Límite: Humans / Male Idioma: En Revista: Int J Surg Pathol Asunto de la revista: PATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Tumores Neuroendocrinos / Carcinoma de Células Pequeñas / Carcinoma Neuroendocrino / Carcinoma de Células Grandes / Carcinoma de Células Acinares Tipo de estudio: Guideline / Prognostic_studies / Qualitative_research Límite: Humans / Male Idioma: En Revista: Int J Surg Pathol Asunto de la revista: PATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: India